Compare Citius Pharmaceuticals Inc (CTXR) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Boston Beer Company Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Boston Beer Company Inc trades at $171.02 (market cap $1.76B). The key difference: Boston Beer Company Inc is far larger — about 129.2× Citius Pharmaceuticals Inc's market cap, and Boston Beer Company Inc is more actively traded (264,496 versus 132,438). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Boston Beer Company Inc for 59 Days on average.
| CTXR | SAM | |
|---|---|---|
Market Cap | $13.62M | $1.76B |
Volume | 132,438 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $260.05 |
52-Week Low | $0.48 | $161.08 |
Typical Hold Time | 16 Days | 59 Days |
Enterprise Value | $3.79M | $1.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Boston Beer Company (SAM) trades at $171.33, up 1.89% with a bullish technical signal despite mixed earnings performance. The stock shows strong cash flow generation with $270M operating cash flow in 2025, but faces profitability challenges with negative net income margin of -3.64%. Recent developments include new product launches and marketing initiatives targeting younger demographics, while analyst consensus remains cautious with 72% hold ratings.
SAM presents a mixed investment case with attractive valuation metrics (P/E 22.7, P/S 0.94) offset by profitability concerns. Upside potential exists from innovation initiatives and brand investments, but investors face risks from volume declines and competitive pressures. The stock trades near consensus price target of $204.44, suggesting moderate upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
